Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Summit Therapeutics Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.78 (market cap $3.06B), while Summit Therapeutics Inc trades at $17.32 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 4.5× State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF's market cap, and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 15 Days and Summit Therapeutics Inc for 16 Days on average.
| FLRN | SMMT | |
|---|---|---|
Market Cap | $3.06B | $13.71B |
Volume | 6,296,473 | 6,173,057 |
Sector | Fixed Income | Health |
52-Week High | $30.86 | $26.38 |
52-Week Low | $30.65 | $12.43 |
Typical Hold Time | 15 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.75 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with strong selling pressure in moving averages, while oscillators remain neutral. The ETF maintains consistent $0.11 quarterly dividend payments through 2026, providing income stability amid current market volatility.
FLRN offers protection against rising interest rates with near-zero duration exposure, though significant financial sector concentration presents risk. Current market sentiment reflects cautious optimism as institutional investors add positions while technical indicators suggest near-term pressure. The floating rate structure positions FLRN favorably in inflationary environments.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
